Catapult Therapeutics is a biotech company developing CAP-100, a humanized anti-CCR7 antibody. It is a humanized IgG1 monoclonal antibody that specifically binds to human CCR7 and neutralizes ligand-mediated signaling through both CCL19 and CCL21. CAP-100 can be used to block migration of tumor cells to lymph nodes, induce tumor cell killing, and inhibit tumor cell survival in the lymph node.